AstraZeneca reports H1 2026 results with revenue up 6%.
Core EPS increased 11% driven by strong execution and investment in transformative technologies.
Latest AstraZeneca News & Updates
See the latest news and media coverage for AstraZeneca. We track all announcements, press releases, and industry mentions in real time, all in one place.
Science-led biopharmaceutical company
astrazeneca.com- Headquarters
- Cambridge, United Kingdom
- Company type
- Public company
- Number of employees
- 80,000+
- Industry
- Pharmaceuticals
Last updated
Latest news about AstraZeneca
In short: AstraZeneca reported double-digit oncology growth and strong Q2 earnings, though its 2030 revenue goals faced mixed pipeline results.
Company announcements
AstraZeneca will share its H1 2026 performance update
The update will be released at 07:00 BST on 27 July 2026, with a webcast at 11:45 BST.
AstraZeneca's camizestrant delayed progression by 55% in breast cancer trial
The Phase III SERENA-6 trial also showed a 37% reduction in risk of second progression and 51% of patients achieved total ctDNA clearance.
AstraZeneca shows 30% PFS risk reduction in EMERALD-3
In EMERALD‑3 Phase III, STRIDE plus lenvatinib and TACE improved median PFS to 13.0 months versus 9.8 months and showed a positive OS trend.
Media coverage
AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
UK drugmaker AstraZeneca has been exploring a deal to combine with U.S. rival Bristol Myers Squibb ...
USA's vaccine resistance can put Södertälje in the line of fire
Donald Trump pressures Health Minister Robert F. Kennedy Jr to reduce vaccination recommendations, which threatens AstraZeneca's RSV protection Beyfortus manufactured in Södertälje.
AstraZeneca's drug pipeine is splitting opinion among City analysts
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drug pipeline is splitting opinion among City brokers, with Citibank upgrading its price target to 17,800p whilst analysts at Deutsche Bank...
AstraZeneca reports Phase III results for Ultomiris and Sone-Ve
In the ALXN1210-TMA-313 Phase III trial, Ultomiris did not achieve statistical significance for event-free survival.
Never miss news about AstraZeneca
Track AstraZeneca and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
AstraZeneca competitors & trending companies
Browse news for competitors to AstraZeneca and other trending companies.